Tagged with B

China The phenomenal success of the Pfizer/BioNTech and Moderna COVID-19 vaccines has catapulted messenger RNA (mRNA) vaccines into public consciousness, and mRNA technology is today receiving more scientific and financial attention than ever before. Suzhou, China-based biotech Abogen, for example, which has an mRNA-based COVID vaccine in late-stage development, has received…

Denmark Catherine Mazzacco’s two-year stint as CEO of Danish dermatology specialist LEO Pharma is over. With the company’s board planning for an initial public offering (IPO) within the next four-to-five years, LEO is now on the lookout for a replacement with capital market experience and the ability to steer the firm…

Spain A rundown of five things to know about the healthcare and life sciences industry in Catalonia. Nestled in Northeastern Spain and bordering France, Catalonia’s capital and largest city is Barcelona. The region boasts a strong scientific output by European standards, is the birthplace of many of Spain’s pharma success stories,…

Denmark Denmark boasts plenty of strong fundamentals as a clinical trials hub, but is perhaps constrained by a population of just 5.8 million and a correspondingly small patient pool. However, international collaboration, not least with neighbouring Sweden (population 10.4 million), has the potential to greatly increase the pool from which trial…

Global Shawview Consulting’s Brendan Shaw laments the descent into nationalism that COVID-19 – like past pandemics – has led to, and outlines his hopes that the World Health Assembly’s new accord on pandemic prevention, preparedness and response will lead to a more unified, global approach to future pandemics.   When Professor…

Saudi Arabia Myriam Hakim outlines the progress that Japanese rare disease and oncology specialist Kyowa Kirin has made in the GCC region in recent years; the importance of the Saudi market to Kyowa Kirin and its customised strategy there; as well as the main game-changers for patients in the region, namely the…

Denmark Speaking exclusively to PharmaBoardroom, Jan van de Winkel highlights the tremendous progress that European biotech success story Genmab has made over the past six years, how its partnership model is evolving, Denmark’s continuing relevance to the company, and Genmab’s value proposition for the next generation of talent.   Genmab has…

Denmark Speaking after the recent completion of a three-year strategic transformation plan, ALK President and CEO Carsten Hellmann outlines the progress made by the Danish allergy giant under his stewardship, including deeper penetration of the US market, shifting from injections to tablets, and driving digitalisation and efficiency.   To put our…

Global Marc Boutin, Novartis’ global head of patient engagement, outlines the company’s “bold vision” of patient engagement and the actions that need to be taken for CAR-T patients in the immediate, short- medium-, and long-term. This piece forms part of our special section, InFocus: Patient Engagaement in the Era of CAR-T.…

Denmark Denmark’s four largest pharma companies – Novo Nordisk, Lundbeck, LEO Pharma, and ALK – are all at least partly owned by independent foundations, which means that their profits are divided between their shareholders and the foundations themselves, with funds then channelled into academia and biotech start-ups. Here, a variety of…

Saudi Arabia Fahad Al Shebel is CEO of NUPCO, the centralised procurement body for healthcare products to Saudi Arabia’s government health sector. In a wide-ranging interview, Al Shebel describes NUPCO’s evolution to today provide a broad range of services, its central role in fighting the COVID-19 pandemic, digitalization initiatives, and how its…

Saudi Arabia Dr. Nada Abu-Shraie gives her insights into the evolving drug evaluation processes in Saudi Arabia, including the progress made on the path towards striking value-based agreements, where the country stands in terms of patient registries and epidemiological data, and Vision 2030’s potential impact on the medicine reimbursement landscape. We hope…